End Stage Renal Disease. Chronic kidney disease, stage 5
Conditions
Interventions
Intervention 1: Intervention group: 2 g of Pomegranate extract before every dialysis session for 8 weeks. Intervention 2: control group: 4 capsules of placebo before every hemodialysis session.
Treatment - Drugs
Placebo
Intervention group: 2 g of Pomegranate extract before every dialysis session for 8 weeks
control group: 4 capsules of placebo before every hemodialysis session
Sponsors
Vice-Chancellor for Research and Technology Affairs
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: ESRD patients on chronic hemodialysis for at least three consecutive months Exclusion criteria: history of hypersensitivity to pomegranate; kidney transplant less than 6 months before study enrollment; vitamin E (60 IU/day or more), vitamin C (500 mg/day or more), or other antioxidant supplements during the month before the study; history of hospitalization during 3 months before the study; patients with life-threatening comorbidities including malignancies; being severely deconditioned
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CRP. Timepoint: before and after the intervention. Method of measurement: blood sample.;Hemoglobin. Timepoint: before and after the intervention. Method of measurement: blood sample.;Leptin. Timepoint: before and after the intervention. Method of measurement: blood sample.;Nutritional status. Timepoint: before and after the intervention. Method of measurement: MIS.;IL-6. Timepoint: before and after the intervention. Method of measurement: blood sample. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse drug reactions. Timepoint: during intervention. Method of measurement: patient-based reports. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Jamshid Roozbeh
Shiraz University of Medical Sciences, Nephrology Department
Outcome results
None listed